Scharpenseel et al. [97] found that by combining EpCAM enrichment with EGFR- and HER3-based enrichment, CTCs can be detected in a large proportion of NSCLC patients, including brain metastatic patients who were previously found to have only very few EpCAM positive CTCs. This evidence concerns the gene EPCAM and non-small cell lung carcinoma.